查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465588

连续生物加工市场规模 - 按产品[仪器、消耗品]、营运规模、製程、应用、最终用户和全球预测 2024 - 2032

Continuous Bioprocessing Market Size - By Product [Instruments, Consumables], Scale of Operation, Process, Application, End-user & Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在该领域领先公司的进步和成就的推动下，2024 年至 2032 年间，全球连续生物加工市场的复合年增长率将超过 22.1%。随着公司不断创新和开发新技术，生物加工产业正在经历向连续製造方法的转变。例如，2023年11月，全球知名合约研究、开发和製造组织（CRDMO）药明生物揭露了利用WuXiUPTM实现端到端DS中试生产的成果。这种具有超高生产率的专有连续生物加工平台在其非 GMP 试点工厂实施。

这些进步包括整合和自动化系统的开发、一次性技术以及改进的监控和控制策略。领先公司在製程效率、产品品质和可扩展性方面取得了显着的里程碑，推动了连续生物製程在各种生物製药应用中的采用。此外，连续生物加工还具有降低成本、提高生产力和加快上市时间等优势，进一步刺激了市场需求。随着该行业接受这些创新，连续生物加工市场预计将在未来几年实现大幅成长和扩张。

整个连续生物加工产业根据产品、经营规模、製程、应用、最终用户和地区进行分类。

耗材领域将在2024年至2032年经历严格的发展。 。这些消耗品在实现高效且可扩展的连续生物加工操作方面发挥着至关重要的作用。此外，与传统不銹钢设备相比，它们还具有降低交叉污染风险、更快的周转时间和更低的营运成本等优势。随着全球生物製药生产能力的不断扩大，连续生物加工市场对耗材的需求将持续稳定成长。

从2024 年到2032 年，研发领域的连续生物加工市场份额将实现显着的复合年增长率。和更快的开发时间表。随着生物製药公司寻求简化其研发工作并加快新疗法的上市时间，连续生物加工的采用正在迅速获得关注。它能够促进连续资料生成、流程优化以及从小规模实验到商业生产的放大，使其成为现代生物製药研发工作中不可或缺的工具。因此，连续生物加工可望重塑生物製药创新和发展的格局。

亚太连续生物加工市场从 2024 年到 2032 年将呈现出值得称讚的复合年增长率。此外，不断增加的研发投资以及政府促进生物技术的措施正在推动市场成长。亚太地区作为药品和生物製剂製造中心的战略重要性进一步推动了对连续生物加工解决方案的需求。因此，亚太市场正成为连续生物加工市场全球扩张的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 对生物製药的需求不断增加
      • CMO 和 CDMO 越来越多地采用连续生物工艺
      • 连续生物加工技术的进步
    • 产业陷阱与挑战
      • 设备成本高
      • 严格的监管要求
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

  • 主要趋势
  • 仪器
    • 色谱系统
    • 过滤系统和装置
    • 生物反应器
    • 其他仪器
  • 耗材
    • 细胞培养基和缓衝液
    • 试剂

第 6 章：市场估计与预测：按营运规模划分，2018 年 - 2032 年

  • 主要趋势
  • 商业的
  • 研究与开发

第 7 章：市场估计与预测：按流程划分，2018 年 - 2032 年

  • 主要趋势
  • 下游生物过程
  • 上游生物工艺

第 8 章：市场估计与预测：按应用划分，2018 年 - 2032 年

  • 主要趋势
  • 单株抗体
  • 疫苗
  • 细胞和基因治疗
  • 其他应用

第 9 章：市场估计与预测：按最终用户划分，2018 年 - 2032 年

  • 主要趋势
  • 製药和生物技术公司
  • CMO 和 CRO
  • 研究和学术机构

第 10 章：市场估计与预测：按地区，2018 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 11 章：公司简介

  • 3M Company
  • Bionet
  • Danaher Corporation (Pall Corporation)
  • Eppendorf SE
  • FUJIFILM HOLDINGS CORPORATION
  • Merck KGaA
  • Repligen Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics
简介目录
Product Code: 8350

Global Continuous Bioprocessing Market will witness over 22.1% CAGR between 2024 and 2032, propelled by advancements and achievements from leading companies in the field. As companies continue to innovate and develop novel technologies, the bioprocessing industry is experiencing a transformation towards continuous manufacturing methods. For instance, in November 2023, WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), disclosed the achievement of end-to-end DS manufacturing at a pilot scale, utilizing WuXiUPTM. This proprietary continuous bioprocessing platform with ultra-high productivity was implemented at its non-GMP pilot plant.

These advancements include the development of integrated and automated systems, single-use technologies, and improved monitoring and control strategies. Leading companies are achieving remarkable milestones in process efficiency, product quality, and scalability, driving the adoption of continuous bioprocessing across various biopharmaceutical applications. Moreover, continuous bioprocessing offers advantages such as reduced costs, increased productivity, and faster time-to-market, further fueling market demand. As the industry embraces these innovations, the Continuous Bioprocessing Market is poised for substantial growth and expansion in the coming years.

The overall Continuous Bioprocessing Industry is classified based on the product, scale of operation, process, application, end-user, and region.

The consumables segment will undergo rigorous development from 2024 to 2032. As the biopharmaceutical industry increasingly adopts continuous manufacturing methods, the demand for consumables such as single-use bioreactors, filtration systems, chromatography columns, and sensors is on the rise. These consumables play a crucial role in enabling efficient and scalable continuous bioprocessing operations. Moreover, they offer advantages such as reduced risk of cross-contamination, faster turnaround times, and lower operating costs compared to traditional stainless-steel equipment. With the continuous expansion of biopharmaceutical manufacturing capacities worldwide, the demand for consumables in the Continuous Bioprocessing Market could continue growing steadily.

The continuous bioprocessing market share from the research and development segment will register a notable CAGR from 2024 to 2032. Continuous bioprocessing offers numerous advantages over traditional batch processes, including enhanced process control, reduced manufacturing footprint, and faster development timelines. As biopharmaceutical companies seek to streamline their R&D efforts and accelerate the time-to-market for new therapies, the adoption of continuous bioprocessing is rapidly gaining traction. Its ability to facilitate continuous data generation, process optimization, and scale-up from small-scale experiments to commercial production makes it an indispensable tool in modern biopharmaceutical R&D endeavors. Thus, continuous bioprocessing is poised to reshape the landscape of biopharmaceutical innovation and development.

Asia Pacific continuous bioprocessing market will showcase a commendable CAGR from 2024 to 2032. Rapid industrialization, in line with the expanding biopharmaceutical sector in countries like China, India, and South Korea, is driving the demand for advanced bioprocessing technologies. Moreover, increasing investments in research and development, alongside government initiatives promoting biotechnology, are fueling market growth. The Asia-Pacific region's strategic importance as a manufacturing hub for pharmaceuticals and biologics further boosts demand for continuous bioprocessing solutions. As a result, the Asia-Pacific market is emerging as a significant contributor to the global expansion of the Continuous Bioprocessing Market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data validation
  • 1.4 Data collection
  • 1.5 Forecast parameters
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for biopharmaceuticals
      • 3.2.1.2 Growing adoption of continuous bioprocessing among CMOs and CDMOs
      • 3.2.1.3 Advancements in continuous bioprocessing technologies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High equipment cost
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
    • 5.2.1 Chromatography systems
    • 5.2.2 Filtration systems and devices
    • 5.2.3 Bioreactors
    • 5.2.4 Other instruments
  • 5.3 Consumables
    • 5.3.1 Cell culture media & buffers
    • 5.3.2 Reagents

Chapter 6 Market Estimates and Forecast, By Scale of Operation, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Commercial
  • 6.3 Research and development

Chapter 7 Market Estimates and Forecast, By Process, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Downstream bioprocess
  • 7.3 Upstream bioprocess

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Monoclonal antibodies
  • 8.3 Vaccines
  • 8.4 Cell and gene therapy
  • 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical and biotechnology companies
  • 9.3 CMOs and CROs
  • 9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 3M Company
  • 11.2 Bionet
  • 11.3 Danaher Corporation (Pall Corporation)
  • 11.4 Eppendorf SE
  • 11.5 FUJIFILM HOLDINGS CORPORATION
  • 11.6 Merck KGaA
  • 11.7 Repligen Corporation
  • 11.8 Sartorius AG
  • 11.9 Thermo Fisher Scientific Inc.
  • 11.10 WuXi Biologics